Mycosis Fungoides
Welcome,         Profile    Billing    Logout  
 64 Companies   101 Products   101 Products   73 Mechanisms of Action   1 Trial   336 News 


12345678»
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Phase classification, Combination therapy:  Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) -  Jan 24, 2024   
    P1,  N=3, Terminated, 
    Completed --> Active, not recruiting | Trial completion date: Dec 2013 --> Dec 2025 Phase classification: P1/2 --> P1
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment change, Trial withdrawal:  Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma (clinicaltrials.gov) -  Nov 26, 2018   
    P2,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=30 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Oxsoralen (methoxsalen topical lotion) / Bausch Health
    Trial completion, Trial completion date, Trial primary completion date:  M_PUVA_2012: PUVA Maintenance Therapy in Mycosis Fungoides (clinicaltrials.gov) -  Jul 20, 2018   
    P3,  N=28, Completed, 
    Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> Jul 2018 | Trial primary completion date: Oct 2021 --> Jul 2018
  • ||||||||||  Tavo (tavokinogene telsaplasmid) / OncoSec
    Trial termination, Trial primary completion date:  Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma (clinicaltrials.gov) -  Jan 3, 2018   
    P2,  N=2, Terminated, 
    Active, not recruiting --> Completed Completed --> Terminated | Trial primary completion date: Mar 2016 --> Jun 2014; Due to company resource constraints
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Trial completion, Trial primary completion date, Metastases:  Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma (clinicaltrials.gov) -  Oct 19, 2017   
    P2,  N=37, Completed, 
    Completed --> Terminated | Trial primary completion date: Mar 2016 --> Jun 2014; Due to company resource constraints Active, not recruiting --> Completed | Trial primary completion date: Sep 2018 --> Oct 2017
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial primary completion date:  COMBOSTAT: Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (clinicaltrials.gov) -  Sep 19, 2017   
    P2,  N=0, Withdrawn, 
    Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012 Trial primary completion date: Apr 2014 --> May 2012
  • ||||||||||  Trial completion, Trial primary completion date:  Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) -  May 24, 2017   
    P2,  N=9, Completed, 
    Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Mar 22, 2017   
    P=N/A,  N=17, Completed, 
    Trial primary completion date: Sep 2017 --> Sep 2018 Active, not recruiting --> Completed | N=100 --> 17 | Trial primary completion date: Dec 2016 --> Feb 2012
  • ||||||||||  Oxsoralen (methoxsalen topical lotion) / Bausch Health
    Enrollment closed, Enrollment change:  M_PUVA_2012: PUVA Maintenance Therapy in Mycosis Fungoides (clinicaltrials.gov) -  Jan 12, 2017   
    P3,  N=28, Active, not recruiting, 
    Active, not recruiting --> Terminated; slow accrual Recruiting --> Active, not recruiting | N=82 --> 28
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Rituxan (rituximab) / Roche
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy:  CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Aug 15, 2016   
    P1,  N=1, Active, not recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Feb 2015; Slow Accruals Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016
  • ||||||||||  lenalidomide / Generic mfg.
    Trial primary completion date, Metastases:  Lenalidomide Maintenance Post-debulking in Advanced CTCL (clinicaltrials.gov) -  Jul 19, 2016   
    P3,  N=21, Terminated, 
    Recruiting --> Active, not recruiting | N=14 --> 1 | Trial primary completion date: Dec 2016 --> Aug 2016 Trial primary completion date: Apr 2016 --> Sep 2013
  • ||||||||||  Epogen (epoetin alfa) / Amgen
    Trial completion:  Epoetin Alfa in Treating Anemia in Patients With Solid Tumors (clinicaltrials.gov) -  Jul 16, 2016   
    P3,  N=365, Completed, 
    Trial primary completion date: Apr 2016 --> Sep 2013 Active, not recruiting --> Completed